Fennec Pharmaceuticals Inc. announced on March 4, 2026, that Tampa General Hospital Cancer Institute is initiating a real-world study evaluating the clinical utility of PEDMARK® (sodium thiosulfate injection) in reducing ototoxicity risk in adolescent, young adult, and adult cancer patients receiving cisplatin-based chemotherapy.
Key takeaways
Tampa General Hospital Cancer Institute initiating real-world study of PEDMARK® on March 4, 2026
Study evaluates PEDMARK® in reducing ototoxicity in AYA and adult patients with non-metastatic solid tumors on cisplatin chemotherapy
PEDMARK® FDA-approved for pediatric patients 1 month+ with localized non-metastatic solid tumors
PEDMARK® has NCCN 2A recommendation for AYA patients
Study led by Gene A. Wetzstein, PharmD, BCOP, Director of Supportive Care Research at TGH Cancer Institute